A novel SLC8A1/LINC01913 intergenic region-ALK fusion identified by NGS and validated by IHC and FISH in a stage IIB lung adenocarcinoma patient who remains relapse-free during the treatment of crizotinib: a case report [0.03%]
NGS和IHC及FISH验证的新型SLC8A1/LINC01913间质区-ALK融合基因在克唑替尼治疗中未复发IIB期肺腺癌患者中的发现及报道：病例报告
Chunguang Wang,Shu Chen,Qianru He et al.
Chunguang Wang et al.
In resected non-small cell lung cancer (NSCLC), ALK rearrangements are associated with worse recurrence-free survival (RFS) than other driver genes. In addition, the micropapillary pattern of NSCLC is associated with a poor prognosis. In re...
Dacomitinib overcomes afatinib-refractory carcinomatous meningitis in a lung cancer patient harbouring EGFR Ex.19 deletion and G724S mutation; a case report [0.03%]
达可替尼成功治疗艾乐替尼耐药的EGFR 19缺失突变合并G724S突变非小细胞肺癌脑膜转移一例报告
Kei Kunimasa,Naotoshi Sugimoto,Motohiro Tamiya et al.
Kei Kunimasa et al.
It has been reported that the efficacy of EGFR-TKI is predicted, not by which exon of the EGFR gene is mutated, but by the structural change in the EGFR protein due to the mutation. Here, we present an EGFR-mutated lung cancer patient with ...
Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study [0.03%]
AMG 232联合MAPK抑制剂在转移性黑色素瘤中靶向野生型TP53的Ⅰ期临床研究
Stergios J Moschos,Shahneen Sandhu,Karl D Lewis et al.
Stergios J Moschos et al.
Background: Targeting the MDM2-p53 interaction using AMG 232 is synergistic with MAPK inhibitors (MAPKi) in preclinical melanoma models. We postulated that AMG 232 plus MAPKi is safe and more effective than MAPKi alone in...
The return of RET GateKeeper mutations? an in-silico exploratory analysis of potential resistance mechanisms to novel RET macrocyclic inhibitor TPX-0046 [0.03%]
RET门控保镖突变的卷土重来？对新型RET大环抑制剂TPX-0046潜在耐药机制的探索性分析
Matteo Repetto,Edoardo Crimini,Liliana Ascione et al.
Matteo Repetto et al.
TPX-0046 is designed to overcome resistance to FDA approved RET inhibitors Selpercatinib and Pralsetinib. Early prediction of resistance mechanisms to investigational drugs may facilitate subsequent drug and trial designs. This study aims t...
Dramatic response to alectinib in a lung adenocarcinoma patient harboring a Novel SSFA2-ALK fusion [0.03%]
一种新型SSFA2-ALK融合阳性的肺腺癌患者接受阿来替尼治疗后表现出戏剧性反应
Xinyi Lin,Xiaojuan Yang,Yuan Tan et al.
Xinyi Lin et al.
ALK (anaplastic lymphoma kinase) gene rearrangements have been reported in 3-5% of NSCLC patients. Different ALK fusion forms can mediate different downstream signaling pathways and may exhibit different sensitivities to ALK tyrosine kinase...
Rare ocular toxicity induced by pertuzumab/QL1209 in healthy chinese subjects: case reports and whole-exome sequencing analysis [0.03%]
帕妥珠单抗/QL1209在健康受试者中的罕见眼部毒性：病例报告及外显子组测序分析
Junlong Ma,Wenjing Chen,Zhanqing Hu et al.
Junlong Ma et al.
Pertuzumab is a recombinant anti-HER2 humanized monoclonal antibody widely used for the adjuvant treatment of HER2-positive breast cancer. Its safety is well established with the most common adverse effects being diarrhea and rash. To our k...
A phase Ib dose escalation study of oral monotherapy with KX2-391 in elderly patients with acute myeloid leukemia [0.03%]
KX2-391口服单药治疗老年急性髓系白血病患者的Ib期剂量递增研究
Margaret T Kasner,Molly B Halloran,Jonathan Pan et al.
Margaret T Kasner et al.
Poor tolerance to standard therapies and multi-drug resistance complicate treatment of elderly patients with acute myeloid leukemia (AML). It is therefore imperative to explore novel tolerable agents and target alternative pathways. KX2-391...
Selinexor synergizes with azacitidine to eliminate myelodysplastic syndrome cells through p53 nuclear accumulation [0.03%]
选择性核输出抑制剂Selinexor联合地西他滨通过诱导p53核积累高效杀伤骨髓增生异常综合征细胞
Yixuan Guo,Zhaoyun Liu,Lixiang Duan et al.
Yixuan Guo et al.
Myelodysplastic syndromes (MDS) are clonal malignancies of multipotent hematopoietic stem cells, characterized by ineffective hematopoiesis leading to cytopenia. Hypomethylating agents, including azacitidine, have been used for treating MDS...
A lung adenocarcinoma patient harboring MET c. 3028 + 2 T >A variant sensitive to crizotinib treatment [0.03%]
携带MET外显子14跳越变异的腺癌肺癌患者对克唑替尼治疗敏感
Rui Jiang,Dongguang Wei,Yuan Tan et al.
Rui Jiang et al.
Several studies have reported that patients harboring MET-ex14 skipping benefit from MET tyrosine kinase inhibitors (TKIs) such as crizotinib, however, the overall response of crizotinib was 32% in these patients. Therefore, the clinical ou...
Guanglin Shi,Yuyan Luo,Zhaonan Yu et al.
Guanglin Shi et al.
Background: REarranged during Transfection (RET) gene fusion is one of the common oncogenic variants detectable in non-small cell lung cancer (NSCLC). The feature of most oncogenic RET gene fusion cases is that RET tyrosi...